Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
voxvoganan
- Development stage
- Phase 2
- Lead developer
- Lytix Biopharma
- Modality
- Modified Peptides → Peptides, Small Molecules
- Administration
- Topical, Intranasal
01
Overview
Voxvoganan (LTX-109) is a synthetic broad-spectrum antimicrobial peptidomimetic designed for topical use. It is a tripeptide derivative that acts by disrupting microbial cell membranes through rapid lytic activity, leading to cell lysis and death. This mechanism mimics innate immune effectors known as lytic peptides. Voxvoganan has demonstrated potent bactericidal activity against Gram-positive bacteria—including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate and -resistant S. aureus (VISA/VRSA)—as well as efficacy against bacterial and fungal biofilms[3][4][5][7]. It also exhibits virucidal effects in vitro against SARS-CoV-2 and Influenza A[10]. The drug has a low propensity for resistance development due to its novel membrane-targeting action[5][8]. Clinical trials have explored its use in nasal decolonization of S. aureus (including MRSA/MSSA), skin infections such as impetigo and atopic dermatitis, COVID-19-related respiratory infections, hidradenitis suppurativa, and other Gram-positive skin infections[1][4][6].
- Brand names
- Lytixar
- Other names
- voxvogananUNII-HO813QDF65UNII-HO-813QDF65UNII-HO 813QDF65CHEBI:77752VOXVOGANAN [INN]
Beyond the preview
Go deeper on voxvoganan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on voxvoganan.